Date	Period	Revenue/Estimate	Earnings Call
--	2025/Q1	-- / 79.538B	--
--	2024/Q4	-- / 80.723B	--
Nov 6, 2024	2024/Q3	71.311B / 71.869B	--
Aug 7, 2024	2024/Q2	68.060B / 68.563B	--
May 2, 2024	2024/Q1	65.349B / 63.573B	--

DatePeriodRevenue/EstimateEarnings Call

--2025/Q1-- / 79.538B--

--2024/Q4-- / 80.723B--

Nov 6, 20242024/Q371.311B / 71.869B--

Aug 7, 20242024/Q268.060B / 68.563B--

May 2, 20242024/Q165.349B / 63.573B--

Unlock Free Earnings Estimates

Open Account

6-K: Financial Report for the Period 1 January 2024 to 30 September 2024

Nov 6, 2024 06:37 ET

6-K: Financial Report for the Period 1 January 2024 to 30 June 2024

Aug 7, 2024 06:56 ET

6-K: Novo Nordisk Stops the Ocedurenone CLARION-CKD Trial and Recognises Impairment Loss

Jun 26, 2024 13:22 ET

6-K: Financial Report for the Period 1 January 2024 to 31 March 2024

May 2, 2024 07:18 ET

Symbol Mini Chart % Chg

Unlock the Full List

Analysis

Updated: Jan 19, 2025

Buy

No Data